Silence Therapeutics plc (SLN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Silence Therapeutics plc (SLN) closed at USD 8.98 on 2026-10-14, a change of +22.8 % over the past year, with a market capitalization of USD 581.14M.

Silence Therapeutics plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Silence Therapeutics plc key figures

Previous close

USD 8.98 (2026-10-14)

1-year change

+22.8 %

Market cap

USD 581.14M

Enterprise value

USD 369.81M

P/E ratio (trailing)

-6.88

P/E ratio (forward)

-24.61

EPS (trailing)

-1.36

EPS (forward)

-0.38

PEG ratio

n/a

Price to book

11.49

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.00

Employees

88

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Silence Therapeutics plc and compare it with other stocks.